Aclaris Therapeutics, Inc. (ACRS) earnings date
Feb 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 2 acrs-ex99d1.htm EX-99.1 Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic Dermatitis (AD) - - Positive Primary Analysis Results Announced from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 in AD and Asthma - - Strong Cash Runway Expected to Enable Development of Pipeline Through the First H" exhibit |
| Q3 FY2026 | "Beyond that, we have a series of expected clinical and regulatory milestones throughout the rest of 2026 and 2027, including Phase 2 results in AD from bosakitug and the start of the Phase 2b trial of our oral ITK/JAK3 inhibitor modzatinib in lichen planus, both in the coming few weeks.”" exhibit |
| Q3 FY2026 | "Readout of Top Line Results from Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug Expected in the Fourth Quarter 2026: The randomized, double-blind, placebo-controlled Phase 2 ADMIRATION trial is evaluating the efficacy and safety of bosakitug in 109 patients with moderate-to-severe atopic dermatitis." exhibit |
| Q3 FY2026 | "Initiation of Phase 2b Clinical Trial in Lichen Planus for Investigational Oral ITK/JAK3 Inhibitor Modzatinib Expected in the Fourth Quarter of 2026: Startup activities are ongoing with first site activation expected in November 2026 for this Phase 2b trial in lichen planus, an unaddressed chronic, inflammatory, CD8-driven interface dermatitis." exhibit |
| Q3 FY2026 | "Taking into account the net proceeds from the October offering, the Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the first half of 2029, without giving effect to any potential business development transactions or additional financing activities." exhibit |
| Q2 FY2026 | "EX-99.1 2 acrs-20260806xex99d1.htm EX-99.1 Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 and Phase 2 Trial of Bosakitug (ATI-045) - - Strong Cash Runway Expected to Enable Development of Pipeline Through the End of 2028 - WAYNE, Pa., August 6, 2026 -- Acla" exhibit |
| Q2 FY2026 | "“The first half of 2026 was a period of strong execution across the organization, positioning Aclaris for an exciting second half of the year with numerous expected key catalysts,” stated Dr." exhibit |
| Q2 FY2026 | "Reaffirmed Expectation of Top Line Results in the Second Half of 2026 from Two Ongoing Phase 1b POC Trials of ATI- 052: ATI-052 is being assessed in POC trials in both atopic dermatitis (AD) and asthma." exhibit |
| Q2 FY2026 | "Confirmed Intent to Initiate a Phase 2b Program Encompassing Asthma and AD with ATI-052 in the Fourth Quarter of 2026: Aclaris expects the clinical program to commence with a Phase 2b trial in asthma in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "On Track for Expected Fourth Quarter 2026 Readout of Top Line Results from Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug: Enrollment is complete in this randomized, double-blind, placebo-controlled Phase 2 trial designed to evaluate bosakitug in 109 patients with AD." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ACRS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ACRS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ACRS/"><img src="https://veritasdata.dev/embed/ACRS.svg" alt="ACRS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ACRS/)
Script
<script async src="https://veritasdata.dev/embed/ACRS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ACRS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.